Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 15/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 15/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3237382 | 0.73 | PDPK1 (0.52) | MEN1KMT2A | |
| SCHEMBL3232453 | 0.73 | TRPM8 (0.53) | MEN1KMT2A | |
| SCHEMBL19837388 | 0.70 | P2RX7 (0.47) | HCRTR1HCRTR2P2RX7TAS2R14 | |
| SCHEMBL28914699 | 0.70 | KCNH2 (0.66) | P2RX7TAS2R14 | |
| SCHEMBL868879 | 0.70 | P2RX7 (0.50) | P2RX7TAS2R14 | |
| SCHEMBL29755971 | 0.70 | P2RX7 (0.50) | P2RX7TAS2R14 | |
| SCHEMBL23343864 | 0.69 | P2RX7 (0.45) | HCRTR1HCRTR2P2RX7TAS2R14 | |
| SCHEMBL4664168 | 0.69 | P2RX7 (0.50) | HCRTR1HCRTR2P2RX7TAS2R14 | |
| SCHEMBL8648745 | 0.68 | P2RX7 (0.41) | HCRTR1HCRTR2P2RX7TAS2R14 | |
| SCHEMBL26046016 | 0.68 | P2RX7 (0.49) | HCRTR1HCRTR2P2RX7TAS2R14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745477-B2 | Heteroaryl and benzyl amide compounds | HOFFMAN-LA ROCHE INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-20070185058-A1 | Heteroaryl and benzyl amide compounds | HOFFMANN-LA ROCHE INC. | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185058-A1 | Heteroaryl and benzyl amide compounds | CYP1B1, CYP4B1, ABCG2 | HCRTR1 1602/4885HCRTR2 2272/4885P2RX7 978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.